• Hollywall Entertainment Inc. is a widely diversified technology and broadcasting company, with revenue streams derived from an extensive catalog of music, film, television, software and game library rights
• The company is dedicated to ensuring rural communities largely bereft of reliable communications technology embodied in broadband Internet are able to gain access to quality and affordable services
• The war in Ukraine has served to highlight the importance of Internet access beyond mere entertainment value, as the country’s citizens struggle to maintain “life-saving services online”

Amid the disruptions to society and normal daily activity engendered by the war in Ukraine, the difficulty in maintaining “life-saving services online” and efforts to provide solutions for Ukraine’s citizens highlight the vital importance of delivering Internet access amid crisis (https://ibn.fm/n2csu). While the United States is by no means beset with the armed invasion of a foreign nation, concerns about ensuring “digital equity” through access to the Internet and its resources have long been a focus of telecommunication and broadcasting company Hollywall Entertainment (OTC: HWAL). And with passage of the infrastructure legislative package urged by President Joe Biden last year, the government has become more of a player than ever. The law will “rebuild America’s roads, bridges and rails, expand access to clean drinking water, ensure every American has access to high-speed internet, tackle the climate crisis, advance environmental justice, and invest in communities that have too often been left behind,” according to the White House’s explanation (https://ibn.fm/5cYW6). The high-speed Internet access will be advanced by $65 billion in appropriations through a historic investment in broadband infrastructure deployment, specifically targeting rural and racial minority “unserved” or “underserved” communities, while also delivering lower prices for internet service. A Harvard Business Review census showed that 36.4 percent (16 million) of Black households do not have a computer or broadband access and 70 percent of Black Americans report being under-prepared with digital skills, affecting their employability, leading the late congressman and civil rights icon John Lewis to describe access to the Internet as “the civil rights issue of the 21st century” (https://ibn.fm/RDhuS). Hollywall President and CEO Darnell Sutton helped to pioneer the concept of “Fiber to the People” as a way of empowering small communities, especially those in the South’s “Black Belt,” to pursue the self-determination so central to American ideals. Hollywall’s HW Vision subsidiary, is offering affordable high-speed internet access, tele-health, energy, web conferencing, domain and hosting, IOT, managed internet services, video broadcasting and nationwide unlimited talk, text and data cellular phone plans to its customers. Hollywall derives its revenue from an extensive catalog of music, film, television, software and game library rights, and has announced the pending development of non-fungible tokens (“NFTs”) based on its rights to artists’ works. For more information, visit the company’s website at www.Hollywall.com. NOTE TO INVESTORS: The latest news and updates relating to HWAL are available in the company’s newsroom at https://ibn.fm/HWAL

• Triccar Inc. completed the acquisition of Correlate Inc. and Loyal Enterprises LLC (dba Solar Sight Design) in December last year, setting the wheels in motion for a rebrand
• In a recent news release, the company announced a majority of its shareholders had consented to a name change that will see Triccar Inc. rebrand as Correlate Infrastructure Partners as well as adopt a new symbol, subject to approvals
• The combined company conflates related services that position Correlate Infrastructure Partners to tap into the portfolio energy optimization market, which is valued at $290 billion
• Only 3% of the buildings and infrastructure in the United States are optimized for efficiency, sustainability, renewable energy, and EV support, representing a huge gap that Correlate Infrastructure Partners intends to exploit and grow as a result

Following the late December closing of two acquisitions, Correlate, Inc. and Loyal Enterprises LLC (dba Solar Sight Design), Triccar Inc. embarked on a journey to revamp its brand to better reflect the combined company’s business model and focus moving forward. The journey required consultations with its shareholders as well as the involvement of relevant regulatory and marketplace authorities. Accordingly, in a February 18 news release (https://ibn.fm/9ci5x), the company announced that a majority of its shareholders had, through written consent, approved a name change from Triccar Inc. to Correlate Infrastructure Partners (OTCQB: TCCR). As a result, the company filed a Form 14C Information Statement with the Securities and Exchange Commission (“SEC”) and mailed out the 14C statement to all its shareholders. The company expects to officially change its name to Correlate Infrastructure Partners as well as its ticker symbol upon receiving final approvals from the relevant regulatory and marketplace authorities. “Since the December 2021 merger of two operating companies, Correlate Inc. and Loyal Enterprises LLC (dba Solar Site Design), the company has been aggressively moving to conclude its rebranding, revised web site, investor presentation material, and initiating an investor relations awareness campaign,” commented company CEO Todd Michaels. Todd further expressed excitement at the potential for growth moving forward, especially given that only 3% of the buildings and infrastructure in the U.S are optimized for building efficiency, sustainability, renewable energy, and EV support. The December acquisition, therefore, created a company that can now foray into this space, fill the gaps that may have led to the low optimization rate, and tap into the multi-billion-dollar portfolio energy optimization market. According to the Rocky Mountain Institute, a nonprofit organization working to enhance the clean energy transition, this market has a net present value of $290 billion (https://ibn.fm/Pjagb). The merger conflated two related services: Correlate Inc.’s portfolio-scale development and finance platform, which provides commercial and industrial buildings access to clean solutions oriented toward locally-sited solar, EV infrastructure, energy storage, and smart efficiency measures, and Solar Site Design’s customer acquisition and project development tools for the commercial solar industry. As a result, it created a new data-driven, tech-enabled project development and finance platform aimed at helping industrial and commercial real estate owners augment their net operating income. With the platform, Correlate Infrastructure Partners will provide both portfolio energy optimization and sustainable profit growth for buildings in the United States (https://nnw.fm/xgl4G). (https://ibn.fm/U1c2i). “Correlate [Infrastructure Partners] is a portfolio-scale real estate platform that strives to eliminate the barriers faced by property owners in the pursuit of energy optimization and sustainability goals. Our unique membership platform reduces friction between portfolio managers and service providers by unleashing stakeholders from spreadsheets, vendor fatigue, and any need for upfront capital investment to increase building net operating income,” explains the company’s revamped website (https://ibn.fm/9W1iX). Meanwhile, Correlate Infrastructure Partners expects to file its annual report on Form 10-K on or about March 30. In addition, and according to Todd, the company is in an active acquisition mode throughout 2022 and will update its shareholders accordingly as events unfold. For more information, visit the company’s website at www.CorrelateInfra.com. NOTE TO INVESTORS: The latest news and updates relating to TCCR are available in the company’s newsroom at https://ibn.fm/TCCR

• Globally, there are one billion knowledge workers whose jobs require them to combine action with a level of domain expertise
• Providing these workers with information, tools they need to succeed is key
• Nowigence’s Pluaris app works 24/7 to turn narrative-intensive information into scrollable intelligence

Cultivating and supporting a new generation of knowledge workers is “one of the great challenges of the modern era,” according to a recent “Forbes” article (https://ibn.fm/SZfZ4). Nowigence Inc. (NOWG) is up for the challenge, having created Pluaris, a powerful, proprietary platform that assists readers with automated reading and analysis of textual data. “There are currently about one billion knowledge workers across the globe whose jobs specifically require them to combine action with a level of domain expertise—their knowledge—to generate value and make critical decisions,” the “Forbes” article says. “Some of those decisions seem inconsequential, such as retail layout. But some of them are monumental, even if they seem small, such as the know-how to identify and replace airline parts. “Cultivating a new generation of such knowledge workers is one of the great challenges of the modern era,” the article continued. “Today’s knowledge workers are more global, work across more industries and are not always even in the office. Each of them has a different workflow depending on their job, with their own specific ways to leverage their knowledge.” “Forbes” noted that providing these workers with the information and tools they need to succeed is key to empowering them. “Historically, that simply meant teaching workers to use existing technology. We will have to be more creative than that. Computers, which Apple-founder Steve Jobs famously called ‘the bicycle of the mind,’ are no longer enough, at least in their desktop form. We cannot expect people to have to sit at an office desk to find important information and do their work, a fact made even more clear in the Covid-19 pandemic. We must find new ways to unlock knowledge workers, wherever they are and however they work. The companies that do this will be the ones that leapfrog the competition and change their industries.” Nowigence is committed to doing just that. The company’s Pluaris app works 24/7 to turn narrative-intensive information into scrollable intelligence. The platform automatically scours the web for information based on customized topics of interest, and monitors users’ drives and applications for updates. Pluaris then stores the extracted intelligence in a searchable database. “You may forget what you’ve read, but Pluaris won’t,” the company states, noting that professional knowledge workers include academicians, students, analysts, journalists, editors, researchers, lawyers, programmers, physicians, scientists and more, not to mention personal knowledge workers or individuals who just love to learn. “The intuitive interface makes it easy to drill down to whatever level of detail you require, revealing hidden insights.” Nowigence’s Pluaris offering is the ideal solution to today’s desperate need to support knowledge workers. The company is committed to helping individuals, teams and enterprises quickly distill knowledge from massive amounts of textual data, both public and private. By integrating state-of-the-art data processing techniques in an intuitive interface at an affordable subscription price, Pluaris puts the power of data science into the hands of consumers. For more information, visit the company’s website at www.Nowigence.com. NOTE TO INVESTORS: The latest news and updates relating to Nowigence are available in the company’s newsroom at https://ibn.fm/NOW

• Eat Well Group released a shareholder update letter from the company’s CEO and Director, Marc Aneed, on March 8, 2022, detailing the company’s history, the progress it has made so far along with the plans that it has for the new year
• While appearing on an interview on The Power Play by The Market Herald, Mr. Aneed covered the contents of the shareholder letter while also reiterating how optimistic he is for the company’s future
• He noted that, given the company’s investments so far, the company’s 2022 revenue projections now stand at between $90 million and $110 million

On March 8, 2022, Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) announced a shareholder update letter from Marc Aneed, the company’s Chief Executive Officer (“CEO”) and Director. In the letter, Mr. Aneed highlighted the company’s progress over the eight months it has been in operation. More importantly, it shared the company’s plans and how they tie into its mission to invest in companies that feed families globally while honoring time-valued health and wellness traditions (https://ibn.fm/tRvPl). While appearing on an interview on The Power Play by The Market Herald, Mr. Aneed reiterated the communication on the shareholder update letter, assuring shareholders that the company’s ambitions and long-term growth plans are well aligned, and how the company has managed challenges so far (https://ibn.fm/DzVkX). Mr. Aneed also touched on Eat Well Group’s recent investments, including Belle Pulses, Sapientia Technology, and Amara Organic foods. In the letter, he noted that, through these investments, the company’s collective addressable markets are north of $200 billion, with every one of these businesses serving as a growth engine. He also estimated that, through this growing list of portfolio companies, Eat Well Group has helped offset over 96,250 metric tonnes of methane from the atmosphere, saving “over 874,000 cows’ lives by producing approximately 1.4 billion plant-based burgers.” The letter also walked shareholders through the company’s history and its leadership. “Though we are only eight months old, we’ve been 40 years in the making, with a deep repertoire and history of winning,” Mr. Aneed noted. “The leadership team behind this endeavor has 150 years of collective experience building and investing in world-class businesses, brands, organizations, and systems within the plant-based foods market. We came together to solve one of the most critical gaps in a sector that, by any measure, will amount to billions of dollars of value, all while improving the health of people and pets around the world,” he added. Mr. Aneed remains optimistic that the company’s investments will pay off substantially in the future. While the 2021 year-end financials are yet to be released, he noted that Eat Well Group maintains its guidance in the forecasted range of its investments at around $60 million with bottom-line profitability. Additionally, he stated that financial projections for 2022 remain at between $90 million and $110 million in revenue, with gross margins that will “stand the test of time as the teams drive growth in their respective sectors.” Eat Well Group remains confident about the new year. Its investments so far have paid off and should continue to do so. By pushing the plant-based conversation and combining the best of agribusiness, foodtech, and CPG brands, the company is establishing itself as a leader in its sector. In addition, it is capitalizing on the plant-based food market, projected to be valued at $162 billion by 2030, up from $29.4 billion in 2020. For more information, visit the company’s website at www.EatWellGroup.com. NOTE TO INVESTORS: The latest news and updates relating to EWGFF are available in the company’s newsroom at https://ibn.fm/EWGFF

• Health and wellness drug product innovator Lexaria Bioscience has developed a patented technology — DehydraTECH (TM) — which enhances the bioavailability of fat-soluble drugs and molecules
• Lexaria continues to research DehydraTECH’s ability to improve the speed and bioavailability of cannabidiol (“CBD”) in treating high blood pressure and epileptic conditions
• The company continues its research demonstrating the ability of its technology -to enhance the performance of antiviral drugs and other active pharmaceutical ingredients
• Sublicensing DehydraTECH continues to create revenues for the company
• Lexaria has additionally pursued the use of its drug-enhancing technology, in partnership with sublicensees, for making adult-use recreational cannabis more effective

The potential for drug innovator Lexaria Bioscience’s (NASDAQ: LEXX) patented DehydraTECH(TM) technology to transform the pharmaceutical industry continues to display itself in clinical trials and licensing deals that advance use and awareness of the technology. The company recently announced it has begun animal research to compare effectiveness of FDA-approved Epidiolex to DehydraTECH-CBD for reducing seizure activity. Epidiolex, the world’s only cannabidiol (“CBD”)-based seizure medication to gain approval from the U.S Food and Drug Administration (“FDA“) for treating epileptic conditions (https://ibn.fm/4iZar). Lexaria has analyzed DehydraTECH-enhanced CBD in a variety of applications, the idea being that if DehydraTECH-CBD can enter the bloodstream more rapidly and more potently than CBD that hasn’t been enhanced, then Lexaria can establish the potential benefits of its IP for improving drugs trademarked by other companies. That in turn opens the door to the possibility of high-profile brand-name drugs becoming more effective at lesser dosages, and therefore less expensive as a result. The most immediate benefits in DehydraTECH enhancement are that treated drug products are utilized by the body faster, without any troubling side effects, and that DehydraTECH’s ability to mask any unpleasant tastes eliminates the need to use sweeteners to make the drugs palatable. The technology combines active pharmaceutical ingredients (“APIs”) with a fatty acid oil, applies it to a target compound such as CBD, synthesizes it via a dehydration process and markets the final product as something that can be consumed or combined with a liquid or, in some applications, powders. Reduced filtration by the body’s digestive system makes the product more effective in its use. One marked area of study announced by the company in addition to the new Epidiolex research includes human studies of DehydraTECH-CBD in reducing high blood pressure and potentially being used to treat heart disease (https://ibn.fm/9Fg2g). In non-CBD applications, the DehydraTECH technology has been studied as a means of enhancing the assimilation speed and effectiveness of orally ingested (not inhaled) nicotine, erectile dysfunction drugs such as Viagra and antiviral drugs such as Remdesivir, Ebastine and Colchicine, used in treating COVID-19 patients during the ongoing global pandemic. Each of the research projects has reported astoundingly positive results thus far (https://ibn.fm/znCnN). “Lexaria has a successful track record through strategic partners and licensees who use DehydraTECH technology and have demonstrated improved delivery and performance of tetrahydrocannabinol (“THC”) in both subjective human studies and marketed consumer packaged goods product offerings,” the company stated last year (https://ibn.fm/NMFZl). Lexaria has repeatedly demonstrated that DehydraTECH-processed CBD has superior delivery characteristics into the bloodstream and brain compared to generic CBD and has evidenced similar results with THC. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

On April 5, 2020, beginners, advocates (anyone interested in moving the real estate blockchain space forward), and professionals making a mark in the real estate sector – developers, brokers, traders, policymakers, financiers, startups, and agents – will congregate at the magnificent Hilton Miami Airport Blue Lagoon hotel for the reBLOCKmiami event, set to run from 8.30 am through 5.00 pm. The goal is to learn and network, focused on real estate blockchain, tokenization, non-fungible tokens (“NFTs”), and fintech startups, as well as Decentralized Finance (“DeFi”) real estate, regulatory updates, tradeable private real estate, and buying property in the metaverse. The one-day reBLOCKmiami event will feature more than 25 speakers who currently hold or previously held executive positions in their respective organizations. It also includes a roster of leaders from different associations and governmental bodies, such as Elena Bondarenko, the Government Relations Counsel at Miami Downtown Development Authority, Samuel Armes from the Florida Blockchain Business Association (“FBBA”), and Vince Lago, the Mayor of Coral Gables, Florida. Vince, alongside the Former VP of Hialeah City Council Oscar A. De la Rosa, will at 8.30 am start things off with a presentation dubbed “Morning with the mayors: The vision for crypto and future development.” Their session will kick-start a series of 30-minute talks (presentations and panel discussions), staggered throughout the day, discussing various topics. These include “The future of real estate development in Miami,” “Unlocking liquidity by tokenizing real estate,” “Women in real estate blockchain: Innovating real estate one NFT at a time,” “Bringing tokens to market: From start to finish,” “Regulation: NFTs, digital assets, & real estate,” and more. For a complete list of the scheduled sessions, check out the event plan at (https://ibn.fm/fWPmW). To mark the end of the fulfilling full day of learning, the organizers have scheduled a 1-hour meet-and-greet session between 5.00 pm and 6.00 pm, during which attendees will get a chance to network with their peers and the speakers, exchanging knowledge of the marriage between real estate and crypto/blockchain/DeFi. Thereafter, DJ WildStyle will work the turntables to ensure attendees find their way to the dancefloor at the poolside after-party. The reBLOCKmiami event promises to be a blend of knowledge acquisition, networking opportunities, and fun. The event will officially kick start a series of crypto and blockchain events in Miami set for April 5 to 10 (https://ibn.fm/yySkp). To purchase your ticket, please visit https://reblockmiami.com/tickets/ (different packages are available). For more information on the event, please visit the official website at https://reblockmiami.com. 

• The partnership will see the rebranding of XMarket brick-and-mortar stores in Venice, and Hillcrest, California, under the BESTIES brand
• PlantX is confident that its partnership with BESTIES will accelerate the already significant growth for PlantX
• In the first month of the rebrand, PlantX posted a 30% growth in sales revenue

Over the past year, PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) has embarked on an aggressive expansion campaign to strengthen its retail footprint and bring its products and services closer to consumers. This has seen the opening of various XMarket brick-and-mortar stores in strategic locations, the launch of shop-in-shops within Hudson’s Bay locations, and the acquisition of key brands in the vegan space. In a move that seeks to strengthen its presence in this industry further, PlantX has just announced its retail partnership with BESTIES Vegan Paradise. BESTIES is a leading enterprise in the plant-based space, providing a platform for independent, vegan businesses to contribute to expanding the vegan community (https://ibn.fm/yX9aU). Launched in 2019 by Asia Phoenix and Matt Fontana, BESTIES has grown into one of the key movers in the plant-based space. Through its innovation and its push to enable a plant-based lifestyle among consumers, it has been awarded “Best Grocery Store” in the VegNews Veggie Awards for two consecutive years. PlantX is confident that this partnership will further both companies’ goals to propel plant-based accessibility for all. “Both PlantX and I, personally, are committed to the values and ethics that Asia, Matt, and the BESTIES brand have come to epitomize in the vegan community,” noted Sean Dollinger, the Founder of PlantX. “This partnership will no doubt accelerate the already massive growth for PlantX as we confirm our commitment to those values and cement our place as a leader in the ethical vegan marketplace,” he added. This collaboration with BESTIES has seen PlantX begin redesigning and rebranding its XMarket brick-and-mortar stores in Venice, California, and Hillcrest, California, under the BESTIES brand. In addition, these locations will stock BESTIES branded products such as vegan soft serve. They will also allow orders placed on its e-commerce stores, with same-day deliveries across Los Angeles and San Diego. “We are very thankful to be working so closely with the founders of BESTIES, Matt Fontana and Asia Phoenix, who recognize PlantX as a leader in the vegan space,” said Lorne Rapkin, the Chief Executive officer (“CEO”) of PlantX. “With the knowledge that they too, are industry leaders and want to join forces to roll out their brand with our support is very powerful,” he added. Following this partnership, PlantX has reported an additional 30% in sales revenue for the first month since the Venice location was rebranded to reflect the BESTIES model. In addition, the company’s management is confident that sales will continue increasing, having tapped into a more recognized brand in the plant-based space. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

Noble Capital Markets has announced that Rob Goldman will be a featured Metaverse panelist at NobleCon18, which feature presentations from 120 public companies on April 20 and 21 at The Guitar Hotel near Miami, FL. Joining Facebook (NASDAQ: FB) in 2012 reporting directly to CEO Mark Zuckerberg, Goldman was charged with growing and monetizing the burgeoning social media platforms (including subsidiaries such as Instagram). During his tenure at Facebook, revenues grew from $5 billion to over $70 billion in a span of seven years. Goldman’s move to Facebook happened when his company, Threadsy, was acquired by the social media giant in a move that many refer to as one of “Mark Zuckerberg’s acqui-hires.” Goldman’s company started out as a way for people to see their social feeds and communication from different networks, like Facebook and Twitter, in one place. But Goldman soon changed the focus towards a paid service that helped brands see which influencers they needed to establish relationships with in order to find new customers on social networks. The change resulted in the development of the social marketing tool Swaylo, which ultimately attracted the attention of Zuckerberg. Mr. Goldman is a graduate of Harvard Business School. Admission to NobleCon is free for all levels of investors from self-directed novices to institutional investors, thanks to Noble, Channelchek, Sponsors and The Presenting Companies. Attendance is limited to 1,000. To secure a ticket, visit https://nobleconference.com/register/investor-guest Full list of speakers: https://channelchek.com/news-channel/Scheduled_Speakers_NobleCon18 The presenting companies: https://channelchek.com/news-channel/NobleCon18_Presenting_Companies

• RWB’s mission has always been to become the superior and most recognizable cannabis company in the United States
• It seeks to achieve this by focusing on the continued growth of top-line revenue and bottom-line results through brand expansion, mergers, and acquisitions
• So far, in 2022, the company has announced the acquisition of PharmaCo, which sees the transfer of 21 medical and adult-use cannabis licenses
• RWB has also closed a lease assignment on a critical manufacturing/processing and distribution facility in Michigan
• Its management is confident that the foundations laid down so far will aid in the company’s growth going forward

In 2020, Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) set out on a three-year plan for success. The initial strategy was to form a solid foundation to define its identity while cementing its position in crucial states within the United States. So far, the company has set base in Michigan, Florida, California, and Illinois, in what marks an aggressive and successful expansion plan. “For the balance of 2021 and throughout 2022, the company will focus on the continued growth of our top-line revenue and bottom-line results through expansion of our house of brands that continue to gain momentum, fortification of our vertically integrated businesses, and the synergies from our M&A success,” noted Brad Rogers, the Chairman and Chief Executive Officer (“CEO”) of the company (https://ibn.fm/b9Tf0). In line with these goals and projections, RWB announced the acquisition of PharmaCo, in a transaction initially announced back on July 27, 2020. The purchase sees the transfer of 21 medical and adult-use cannabis licenses to RWB. Additionally, the company now has access to eight fully-operating dispensaries, two operational indoor cultivation facilities, one municipality licensed 10-acre outdoor cultivation facilities, and 22 owned properties for potential additional cultivation and dispensary locations, among others (https://ibn.fm/crX2V). “I’m pleased to announce that we have closed on the PharmaCo acquisition and now control all aspects of our Michigan operations,” noted Mr. Rogers. “This is a major milestone for RWB and its shareholders as we continue to execute key components of our growth strategy and build our house of brands across our core markets, as promised. We are now in the driver’s seat on over 20 assets across Michigan- one of the largest and fastest-growing cannabis markets in the country,” he added. At the beginning of the 2022 calendar year, RWB also closed on a lease assignment for a 15,000 square foot manufacturing/processing and distribution facility in Warren, Michigan. The property already has both medical and adult-use licenses, which allow RWB to begin manufacturing medical and adult-use cannabis products while leveraging a centralized distribution that the existing infrastructure provides (https://ibn.fm/OL1ly). This move also saw RWB’s expansion of its Platinum Vape products and the strengthening of its human resources following the hiring of 30 full-time employees with the objective of growing the number to 50 over the course of the year. Additionally, at the close of the 2021 calendar year, RWB settled a CAD$5.1 million debt and refinanced a CAD$12.8 million acreage Florida acquisition note. It also announced a $6 million year-over-year increase in revenue for the third quarter of the 2021 financial year, representing a 93% growth. In a statement from Mr. Rogers, he noted: “In the third quarter, we made excellent progress in laying additional building blocks in our core operating states of Florida, Michigan, and California to become more vertically integrated where it will be most profitable” (https://ibn.fm/YAyla). The company remains optimistic that the upward trajectory in growth and performance will carry on throughout the 2022 calendar year. The foundations laid down so far line up with the company’s goals and objectives as it gains momentum and fortifies its vertically integrated businesses. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• In a video message to shareholders, CEO John Climaco detailed the operational and clinical progress made by lead drug candidate Berubicin despite market volatility and share price fluctuations
• CNS is currently enrolling patients into a potentially pivotal global drug trial of Berubicin for recurrent glioblastoma multiforme
• Interim analysis of the trial is currently expected as early as the first quarter of 2023, once 30-50% of trial patients have been on the study for six months

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotech company specializing in developing novel treatments for primary and metastatic cancers of the brain and central nervous system, has released a video to its shareholders that reiterates the operational and clinical progress of its lead drug candidate, Berubicin. The video features CNS CEO John Climaco and addresses the recent share price activity (https://ibn.fm/Z40Gw). “The divergence that exists between our operational strength and share price is top of mind for myself and the whole team at CNS Pharmaceuticals. As a shareholder of CNS Pharma, I share in the frustrations as it pertains to the share price and fluctuation in the market – both of which are things out of our control,” Climaco said in his video message. “However, as the CEO, what I do have control over is executing on the day-to-day operations, which I want to reiterate and emphasize have simply never been stronger.” Climaco went on to detail the company’s operational strengths, including the fact that it continues to enroll patients in its potentially pivotal global study of Berubicin in the treatment of adult glioblastoma multiforme (“GBM”). “We have the leading minds in the field around the world working on this trial with us, and we have encouraging ongoing dialogue with the FDA to ensure that our potentially pivotal trial continues to represent the state-of-the-art in the field,” he said. The CNS CEO also underlined that his company remains committed to continuing to execute its operational excellence to drive recognition in the market of Berubicin and its immense potential for patients – the key driver for ultimately generating shareholder value and tremendous hope for GBM patients worldwide. “We put our heads down every day and continue to charge forward in our mission to change the game in glioblastoma via Berubicin,” Climaco added. The video comes days after the company released its full-year 2021 financial results and corporate update, highlighting key milestones during the previous year, including (https://ibn.fm/Lb1r3):

• May 2021 – Beginning of patient enrollment for a potentially pivotal global study evaluating the efficacy of Berubicin for adult recurring GBM
• June 2021 – Granting of Fast Track Designation by the FDA for recurrent GBM treatment with Berubicin
• September 2021 – First patients from potentially pivotal study dosed with Berubicin
• December 2021 – Approval from “swissethics,” the umbrella organization of the Ethics Committee (“EC”) in Switzerland, for the potentially pivotal study of Berubicin for treatment of recurrent GBM to proceed in Switzerland
• January 2022 – Announcement of $11.5 million private placement, priced at the market under NASDAQ rules

CNS plans to expand the potentially pivotal study of Berubicin in recurrent GBM into additional countries and complete the enrollment needed for the interim analysis of the study within the year. The interim analysis of the trial will occur when 30-50% of the total expected patients have been on the study for at least six months, which is anticipated during the first half of 2023. Berubicin is a novel anthracycline and the first that appears to cross the blood-brain barrier. It is currently in development for the treatment of a number of serious brain and oncology indications. The first trial of the drug was initiated by Reata Pharmaceuticals over 16 years ago. It resulted in one patient surviving cancer-free, and two others reporting a reduction in tumor size of up to 80%. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP